Arbutus Biopharma (ABUS) Cash from Operations Growth (3y) (2016 - 2026)

Arbutus Biopharma (ABUS) Cash from Operations Growth (3y) (2016 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Ops. Growth (3y) (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -5.07%
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 33.08%
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 16.64%
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn -7.60%
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Arbutus Biopharma 880.36 Mn 785.13 Mn - 33.28%

Historic Data

Download Data
DateValue
Mar 31, 2026 33.28%
Dec 31, 2025 34.93%
Sep 30, 2025 32.23%
Jun 30, 2025 8.10%
Mar 31, 2025 -38.37%
Dec 31, 2024 19.27%
Sep 30, 2024 -8.95%
Jun 30, 2024 -1.16%
Mar 31, 2024 -2.57%
Dec 31, 2023 -4.82%
Sep 30, 2023 -21.40%
Jun 30, 2023 -30.50%
Mar 31, 2023 -20.89%
Dec 31, 2022 -8.37%
Sep 30, 2022 7.31%
Jun 30, 2022 -4.85%
Mar 31, 2022 48.03%
Dec 31, 2021 -4.72%
Sep 30, 2021 -6.69%
Jun 30, 2021 7.36%